Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 23;9(11):1612.
doi: 10.3390/children9111612.

A Multicenter Cohort Study Evaluating the Teratogenic Effects of Isotretinoin on Neonates

Affiliations

A Multicenter Cohort Study Evaluating the Teratogenic Effects of Isotretinoin on Neonates

Piotr Brzezinski et al. Children (Basel). .

Abstract

(1) Background: Isotretinoin (ISO) is a systemic retinoid known for its teratogenic effects on embryos and fetuses. The aim of this study was to compare the pregnancy outcomes of women who were exposed to isotretinoin with those of women without such exposure from a teratogenic point of view. (2) Methods: A total of 1459 female patients from three clinical hospitals in Poland and Romania, segregated into two groups depending on their ISO exposure, were evaluated between January and December 2019. Medical records were screened to identify the pregnancy outcomes and congenital malformation rates. (3) Results: The congenital malformation rate for the exposed group was 1.2% (four cases), and no specific signs of Accutane embryopathy were identified. Women from the unexposed group were more likely to deliver preterm and through cesarean deliveries and had a higher rate of newborn congenital malformations as compared to women from the exposed group. (4) Conclusions: Even though we could not find a significant association between ISO exposure and teratogenic effects in newborns, effective contraceptive measures are key to preventing unfavorable pregnancy outcomes.

Keywords: contraception; isotretinoin; pregnancy outcomes; teratogenic effect.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

References

    1. Food and Drug Administration (FDA) Roche Pharmaceuticals–Accutane Leaflet. [(accessed on 13 September 2022)];2002 Available online: https://wwwaccessdatafdagov/drugsatfda_docs/label/2008/018662s059lblpdf.
    1. Uysal P.I. Rapid-onset oral isotretinoin-induced acne fulminans apid-onset oral isotretinoin-induced acne fulminans without systemic symptoms in a male adolescent. Our Dermatol. Online. 2021;12:417–418. doi: 10.7241/ourd.20214.14. - DOI
    1. Tounkara T.M.B.H., Soumah M.M., Bangoura M., Diané B.F., Keita M., Kanté M.D., Traoré F.A., Sako F.B., Touré M., Doumbouya A., et al. Severe cutaneous drug reactions in Guinean children: A monocentric retrospective study of 35 cases. Our Dermatol. Online. 2018;9:118–122. doi: 10.7241/ourd.20182.3. - DOI
    1. On S.C., Zeichner J. Isotretinoin updates. Derm. Ther. 2013;26:377–389. doi: 10.1111/dth.12084. - DOI - PubMed
    1. Cammarata-Scalisi F., Nieves D., Avendaño A., Lacruz-Rengel M.A., Alviárez K., Dávila F., Yavuz I., Callea M. Isotretinoin embryopathy: An entity that can be avoided. Arch Argent Pediatr. 2018;116:e303–e307. - PubMed

LinkOut - more resources